Premier Biomedical (BIEI) 0.3500 $BIEI
Premier Biomedical Enters Into Discussions with DOD to Initiate Staged Clinical Trials for Possible Head Trauma Cure
Business Wire - Thu May 08, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that they have initiated discussions with William Beaumont Army Medical Center (WBAMC) at Ft. Bliss, TX toward initiating staged clinical trials to treat soldiers suffering from head trauma leading to clinical depression (PTSD) and possible resultant suicide/homicide ideation. This follows and builds on the successful laboratory work completed by the company and its affiliates to date to measure and eliminate specific molecular compounds from cerebral-spinal fluid (CSF) believed to be responsible for these afflictions.
Premier Biomedical Receives Notice of Allowance on Broad Base Patent
Business Wire - Thu Apr 24, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that their exclusive worldwide licensor, Marv Enterprises, LLC has received a Notice of Allowance from the U.S. Patent and Trademark Office for 20 claims in their broad base patent application, "Utilization of Stents for the Treatment of Blood-Bourne Carcinomas," covering the basic technology underpinning Premier's on-going research into new treatments for many of today's most debilitating diseases.
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Premier Biomedical's CEO Invited to Speak at Brewer Sports Symposium V Featuring High-Level Executives and Industry Leaders Spanning Professional Sports
Business Wire - Thu Apr 10, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) today announced that its President and CEO, William A. Hartman, has been invited to participate in the Brewer Sports Symposium V featuring the 4th Sports Law CLE for Rookies and Veterans taking place in Miami, FL on April 24, 2014. Mr. Hartman is scheduled to speak on the Concussions panel as an expert on Traumatic Brain Injury (TBI) from a science perspective. Representatives from various professional sports organizations including high-level executives and general counsel from the NFL, NHL, NBA and NASCAR are scheduled to participate, along with numerous other presentations and panels to examine and analyze current issues affecting the sports industry today.
Premier Biomedical Continues Progress on Anti-Cancer Treatment
Business Wire - Wed Apr 02, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has prepared and will file a provisional patent application for an anti-breast cancer treatment methodology protocol, in conjunction with its partners in R&D at the Department of Defense (DOD) with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) covering its study accepted for presentation at the American Association for Cancer Research (AACR) annual convention April 7-8, 2014 in San Diego. In addition, the group has discovered and will initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are unique in the industry and very promising.
Premier Biomedical to design clinical trial equipment in partnership with Printed Device Concepts
M2 - Thu Mar 27, 5:55AM CDT
Biopharmaceutical company Premier Biomedical (OTCBB:BIEI) revealed on Wednesday the launch of an agreement to design and fabricate its patent-pending Sequential Dialysis Machine that is critical to advancing its medications and procedures via anticipated clinical trials beginning as early as this calendar year.
Premier Biomedical Signs Agreement To Design Equipment For Clinical Trials
Business Wire - Wed Mar 26, 7:01AM CDT
Premier Biomedical, Inc., (OTCBB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has signed an agreement with Printed Device Concepts, Inc. (PDC) of El Paso, TX to design and fabricate a patent-pending Sequential Dialysis Machine that is critical to advancing the corporation's medications and procedures via anticipated clinical trials beginning as early as this calendar year. Premier has filed over a dozen pending provisional patent applications in the United States and the E.U. addressing a number of diseases previously regarded as incurable or "difficult", such as breast cancer, Alzheimer's disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI). Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI's other R&D partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).
Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development
Marketwire - Wed Mar 12, 7:16AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that through its equity funding arrangement with Kodiak Capital Group, LLC, which was announced in December 2013, it has paid all its liabilities and anticipates having sufficient capital to fund current on-going and mid-term research and development.
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical Inc enters into USD5m equity funding with Kodiak Capital Group LLC
M2 - Tue Dec 17, 5:35AM CST
Biopharmaceutical company Premier Biomedical Inc (OTCBB:BIEI) revealed on Monday the execution of a USD5m common stock purchase agreement with Kodiak Capital Group LLC.
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Marketwire - Mon Dec 16, 7:01AM CST
Premier Biomedical, Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as novel therapies for Alzheimer's disease and traumatic brain injury, announced that it has entered into a $5 million common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach-based institutional investor. The company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC" covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the company has the right at its sole discretion over a period of one year to sell up to $5 million of common stock under the terms set forth in the agreement.
Confirmatory Testing Affirms Prevention of Metastasis in Premier Biomedical Candidate Therapy for Breast Cancer
Marketwire - Thu Dec 05, 7:01AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), in concert with The University of Texas at El Paso, has conducted a confirmatory study supporting the ability of its breast cancer therapy to outperform chemotherapy in mice -- those on this regimen had a distinctively higher survival rate, smaller tumor volume, and maintained weight, as opposed to losing body mass as was demonstrated by control subjects on standard chemotherapy.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
Premier Biomedical Enters Into Discussions with DOD to Initiate Staged Clinical Trials for Possible Head Trauma Cure
Business Wire - Thu May 08, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that they have initiated discussions with William Beaumont Army Medical Center (WBAMC) at Ft. Bliss, TX toward initiating staged clinical trials to treat soldiers suffering from head trauma leading to clinical depression (PTSD) and possible resultant suicide/homicide ideation. This follows and builds on the successful laboratory work completed by the company and its affiliates to date to measure and eliminate specific molecular compounds from cerebral-spinal fluid (CSF) believed to be responsible for these afflictions. Premier Biomedical Receives Notice of Allowance on Broad Base Patent
Business Wire - Thu Apr 24, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that their exclusive worldwide licensor, Marv Enterprises, LLC has received a Notice of Allowance from the U.S. Patent and Trademark Office for 20 claims in their broad base patent application, "Utilization of Stents for the Treatment of Blood-Bourne Carcinomas," covering the basic technology underpinning Premier's on-going research into new treatments for many of today's most debilitating diseases.
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Premier Biomedical's CEO Invited to Speak at Brewer Sports Symposium V Featuring High-Level Executives and Industry Leaders Spanning Professional Sports
Business Wire - Thu Apr 10, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI) today announced that its President and CEO, William A. Hartman, has been invited to participate in the Brewer Sports Symposium V featuring the 4th Sports Law CLE for Rookies and Veterans taking place in Miami, FL on April 24, 2014. Mr. Hartman is scheduled to speak on the Concussions panel as an expert on Traumatic Brain Injury (TBI) from a science perspective. Representatives from various professional sports organizations including high-level executives and general counsel from the NFL, NHL, NBA and NASCAR are scheduled to participate, along with numerous other presentations and panels to examine and analyze current issues affecting the sports industry today.
Premier Biomedical Continues Progress on Anti-Cancer Treatment
Business Wire - Wed Apr 02, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has prepared and will file a provisional patent application for an anti-breast cancer treatment methodology protocol, in conjunction with its partners in R&D at the Department of Defense (DOD) with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) covering its study accepted for presentation at the American Association for Cancer Research (AACR) annual convention April 7-8, 2014 in San Diego. In addition, the group has discovered and will initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are unique in the industry and very promising.
Premier Biomedical to design clinical trial equipment in partnership with Printed Device Concepts
M2 - Thu Mar 27, 5:55AM CDT
Biopharmaceutical company Premier Biomedical (OTCBB:BIEI) revealed on Wednesday the launch of an agreement to design and fabricate its patent-pending Sequential Dialysis Machine that is critical to advancing its medications and procedures via anticipated clinical trials beginning as early as this calendar year.
Premier Biomedical Signs Agreement To Design Equipment For Clinical Trials
Business Wire - Wed Mar 26, 7:01AM CDT
Premier Biomedical, Inc., (OTCBB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has signed an agreement with Printed Device Concepts, Inc. (PDC) of El Paso, TX to design and fabricate a patent-pending Sequential Dialysis Machine that is critical to advancing the corporation's medications and procedures via anticipated clinical trials beginning as early as this calendar year. Premier has filed over a dozen pending provisional patent applications in the United States and the E.U. addressing a number of diseases previously regarded as incurable or "difficult", such as breast cancer, Alzheimer's disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI). Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI's other R&D partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).
Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development
Marketwire - Wed Mar 12, 7:16AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that through its equity funding arrangement with Kodiak Capital Group, LLC, which was announced in December 2013, it has paid all its liabilities and anticipates having sufficient capital to fund current on-going and mid-term research and development.
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical Inc enters into USD5m equity funding with Kodiak Capital Group LLC
M2 - Tue Dec 17, 5:35AM CST
Biopharmaceutical company Premier Biomedical Inc (OTCBB:BIEI) revealed on Monday the execution of a USD5m common stock purchase agreement with Kodiak Capital Group LLC.
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Marketwire - Mon Dec 16, 7:01AM CST
Premier Biomedical, Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as novel therapies for Alzheimer's disease and traumatic brain injury, announced that it has entered into a $5 million common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach-based institutional investor. The company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC"
covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the company has the right at its sole discretion over a period of one year to sell up to $5 million of common stock under the terms set forth in the agreement. Confirmatory Testing Affirms Prevention of Metastasis in Premier Biomedical Candidate Therapy for Breast Cancer
Marketwire - Thu Dec 05, 7:01AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), in concert with The University of Texas at El Paso, has conducted a confirmatory study supporting the ability of its breast cancer therapy to outperform chemotherapy in mice -- those on this regimen had a distinctively higher survival rate, smaller tumor volume, and maintained weight, as opposed to losing body mass as was demonstrated by control subjects on standard chemotherapy.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
